Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 11/16cls
Advanced Life (ADLS) Rodman Elemer Piros Price target Market outperform 4% $2.01
Piros raised his target to $6 from $4 after cethromycin met the primary endpoint of non-inferiority vs. Biaxin clarithromycin in the Phase III CL-05 trial to treat community-acquired pneumonia (CAP). ADLS received rights to the ketolide antibiotic from Abbott (ABT), which markets Biaxin (see B13). He also views ADLS as a strong potential acquisition candidate.
Ambrilia (TSX:AMB) Dundee David Martin Rating change Market outperform (from under review) -10% C$1.05
Martin set a C$2.90 target. He said the $18.7M

Read the full 1021 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE